Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Capstone Therapeutics Reports Q1, First Half Financials
Capstone Therapeutics reported a net loss of $3.1m, or $0.08 per share, for the second quarter of 2009, compared to a net loss of $2.8m or $0.07 per
Capstone Therapeutics reported a net loss of $3.1m, or $0.08 per share, for the second quarter of 2009, compared to a net loss of $2.8m or $0.07 per
The Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a phase 2 clinical trial of Oncophage (vitespen), in combination with
Astellas has received the notice that FDA has substantially denied the company’s Citizen Petition, which had been submitted on September 2007, to ensure the safe and effective use
CytRx has reported that INNO-206 showed to inhibit tumor growth in an experimental animal model of small cell lung cancer (SCLC). INNO-206 is a pro-drug derivative of the
Sanofi-aventis has announced that Multaq (dronedarone) 400mg tablets received Health Canada approval for the treatment of patients with atrial fibrillation, to reduce their risk of cardiovascular hospitalization. Multaq
Dynavax has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAV phase 3 investigational adult hepatitis B vaccine in
Hana Biosciences (Hana) has achieved its enrollment goal of 56 evaluable subjects in the pivotal phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection). It is
AstraZeneca and Forest Laboratories (Forest) have sealed a collaboration agreement to co-develop and commercialise ceftaroline in all markets outside the US, Canada and Japan. Ceftaroline, Forest’s late stage
For the quarter, NovaDel reported a net loss of $1.7m or $0.03 per share, as compared to a net loss of $3.2m or $0.05 per share in the
Ethicon, a Johnson & Johnson company, has revealed that Biopatch Protective Disk with CHG (chlorhexidine gluconate) will include new design elements and updated packaging. The company said that